- Donate
- Understanding Rare Disease
- Living with a Rare Disease
- Community Support
- Advancing Research
- Driving Policy
- Get Involved
- Rare Disease News
- Resource Library
- About Us
- For Clinicians & Researchers
- For Patient Organizations
Last updated: 03/31/2023
Years published: 2023
NORD gratefully acknowledges Kevin McMahon and Gregory Cichon, MD Candidates at Creighton School of Medicine and Nagamani Narayana, DMD, MS, Professor of Dentistry at University of Nebraska Medical Center for the preparation of this report.
Summary
Juvenile ossifying fibroma is a rare and non-cancerous overgrowth of bone in the face or jaw. There are two subtypes of juvenile ossifying fibroma called psammomatoid juvenile ossifying fibroma (PsJOF) and trabecular juvenile ossifying fibroma (TrJOF). Both subtypes primarily affect the bones of the face. PsJOF predominantly affects the bones of the eye and nose and mostly manifests in patients aged 16-33 years. TrJOF predominantly affects the bones of the upper and lower jaw and most commonly affects patients around the age of 8 years. Both forms affect males and females equally.
JOF is considered a โfibro-osseous lesionโ as it is characterized by overgrowth of bone. Both forms of JOF present with slow or rapid, mostly painless, progressive bony overgrowth of the face or jaw. Symptoms may include nasal congestion/ obstruction, eye bulging or double vision. Regardless of type, surgical removal of affected bone is the primary method of treatment. Depending on the amount of bone removed, additional reconstructive or cosmetic surgeries may be required. Due to the high recurrence rate of JOF, continued post-surgical follow-up is essential. The exact cause of JOF is currently unknown and most cases occur sporadically in patients without any family history of the condition.
Introduction
JOF and its subtypes are diagnosed based on the age of the patient affected and biopsy of the bony overgrowth and its location. JOF is not cancerous but may damage surrounding structures or cause significant disfigurement. Patients are often asymptomatic but due to the progressive nature of the lesion, early diagnosis allows for resection of a smaller lesion and less chance of damage to nearby structures.
Most patients with JOF are asymptomatic and have lesions identified incidentally through unrelated imaging such as dental x-rays.
As the fibroma expands either slowly or rapidly, patients may experience non-specific symptoms such as sinus infections (sinusitis), runny nose (rhinorrhea), nosebleeds (epistaxis), nasal obstruction, facial enlargement/changing shape, visual changes, blindness, eyelid drooping (ptosis), bulging of the eye(s) (proptosis/exophthalmos), pain/difficulty with eye movement or papilledema (optic disc bulging) depending on the bones affected. Pain and numbness are often absent but do rarely occur.
The exact cause of JOF is currently unknown, and most cases occur sporadically without any family history of the condition. Some studies suggest that JOF and aggressive behavior in JOF may be driven by a gene change (pathogenic variant or mutation) in a gene on chromosome 12, leading to amplification of genes such as MDM2 and RASAL1. Other studies on PsJOF have identified mutations at nonrandom chromosome breakpoints on the X chromosome at Xq26 and 2q33 leading to translocation of genes between the X chromosome and chromosome 2.
Juvenile ossifying fibroma mostly affects children and adolescents. Patients are generally younger than 15 with an average age of 8-12 years. Both males and females seem to be equally affected. Only 20% of patients are older than 15 at the age of onset.
For TrJOF, which mostly affects the bones of the upper and lower jaw (maxilla > mandible), patients on average are around 8 years old with a range of 2-12 years of age at onset.
For PsJOF, which mostly affects the bones of the eyes or nose (periorbital, ethmoid sinus bones, and frontal sinus bones), patients on average are 16-33 years old with a range of 3-72 years of age at onset.
A diagnosis of JOF may be suspected after imaging for another purpose, such as dental x-rays. The next step is referral to a specialist such as an ear-nose-and throat doctor (ENT) or maxillofacial surgeon who collects samples (biopsies) of the affected bone and may perform additional imaging tests. A pathology laboratory can identify the specific features of the fibroma biopsy sample under a microscope.
Fibromas of each type have a different appearance on imaging, under the microscope, and during surgery that help doctors properly diagnose each type.
Treatment
Juvenile ossifying fibroma is curable through surgery but does have a high tendency to recur after treatment.
After identification, the patient is contacted and scheduled for surgery to remove the affected bone. If the fibroma is large enough, the patient may have additional surgeries for cosmetic purposes or removal or additional affected bone. Finally, patients are scheduled for regular follow-up due to the high risk of the fibroma recurring. Overall, patients generally live normal lives.
Both forms of juvenile ossifying fibromas are benign tumors that may be rapidly or slowly growing; thus both are treated exclusively with aggressive surgery and not with chemotherapy or radiation. JOF tumors are always progressive and will continue to grow without surgical removal. Early recognition of tumors when they are small and/or not invading local structures allows for surgical removal of a smaller area of bone. Tumors that are larger and with greater spread require more significant surgical excisions that remove larger areas of bone and tissue and may require cosmetic surgery to replace bone. Although the fibroma may return after surgery, there have been no reports of fibromas becoming cancerous and spreading to other parts of the body. Smaller tumors may be treated with curettage (scraping away of affected bone), moderate tumors may be treated with surgical excision (cutting away of affected bone) and large tumors may require en bloc resection (surgical removal of the entirety of a fibroma) or resection with reconstruction.
Fibroma recurrence after surgery is not uncommon, which means patients should follow up with their doctor consistently for screening. The more aggressive the original fibroma, the greater chance of it recurring after surgery. If a surgeon is unable to remove the entire fibroma or if the fibroma has grown into nearby structures, it is more likely to recur.
Information on current clinical trials is posted on the Internet at https://clinicaltrials.gov/ All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government website.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
Email: [email protected]
Some current clinical trials also are posted on the following page on the NORD website: https://rarediseases.org/for-patients-and-families/information-resources/info-clinical-trials-and-research-studies/
For information about clinical trials sponsored by private sources, contact:
https://www.centerwatch.com/
For information about clinical trials conducted in Europe, contact:
https://www.clinicaltrialsregister.eu/
TEXTBOOKS
Yepes JF, Stoeckel D. Oral Pathology of the Child and Adolescent. In Dean JA, 11th ed. McDonald and Averyโs Dentistry for the Child and Adolescent. Elsevier; 2022:97-125.
Neville BW, Damm DD, Allen CM, Chi AC. Bone Pathology. In Neville BW, Damm DD, Allen CM, Chi AC, 1st ed. Color Atlas of Oral and Maxillofacial Diseases; Elsevier; 2019:367-410.
Woo SB. Nonodontogenic Intraosseous Tumors. In Woo SB, 2nd ed. Oral Pathology. Elsevier; 2017:441-483.
Schimidt BL. Benign Non-odontogenic Lesions of the Jaws. In: Fonseca R, 3rd ed. Oral and Maxillofacial Surgery. Elsevier; 2016:462-480.
Nelson BL. Benign neoplasms of the gnathic bones. In: Thompson LDR, Golblum JR, 2nd ed. Head and Neck Pathology. Churchill Livingstone; 2013:351-379.
McDonald JS. Tumors of the Oral Soft Tissues and Cysts and Tumors of the Bone. In: Dean JA, Avery DR, McDonald RE, 9th ed. McDonald and Avery Dentistry for the Child and Adolescent. Mosby; 2011:126-149.
El-Mofty SK. Bone Lesions. In Gnepp DR, 2nd edition. Diagnostic Surgical Pathology of the Head and Neck. Saunders; 2009:729-784.
JOURNAL ARTICLES
Khanna J, Ramaswami R. Juvenile ossifying fibroma in themMandible. Ann Maxillofac Surg. 2018 Jan-Jun;8(1):147-150. doi: 10.4103/ams.ams_3_18. PMID: 29963444;
Pandit N, Saini N, Kler S, Jindal S. Juvenile trabecular ossifying fibroma. J Indian Soc Periodontol. 2014 Mar;18(2):232-5. doi: 10.4103/0972-124X.131336.
Zama M, Gallo S, Santecchia L, Bertozzi E, De Stefano C. Juvenile active ossifying fibroma with massive involvement of the mandible. Plastic and Reconstructive Surgery. 2004;113(3):970-974. doi: 10.1097/01.prs.0000105629.56850.aa.
Wenig BM, Vinh TN, Smirniotopoulos JG, Fowler CB, Houston GD, Heffner DK. Aggressive psammomatoid ossifying fibromas of the sinonasal region: a clinicopathologic study of a distinct group of fibro-osseous lesions. Cancer. 1995 Oct 1;76(7):1155-65. doi: 10.1002/1097-0142(19951001)76:7<1155::aid-cncr2820760710>3.0.co;2-p.
INTERNET
Juvenile ossifying fibroma. Genetic and Rare Diseases Information Center (GARD). Feb 2023. https://rarediseases.info.nih.gov/diseases/12792/juvenile-ossifying-fibroma. Accessed March 23, 2023.
NORD strives to open new assistance programs as funding allows. If we donโt have a program for you now, please continue to check back with us.
NORD and MedicAlert Foundation have teamed up on a new program to provide protection to rare disease patients in emergency situations.
Learn more https://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/Ensuring that patients and caregivers are armed with the tools they need to live their best lives while managing their rare condition is a vital part of NORDโs mission.
Learn more https://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/This first-of-its-kind assistance program is designed for caregivers of a child or adult diagnosed with a rare disorder.
Learn more https://rarediseases.org/patient-assistance-programs/caregiver-respite/No patient organizations found related to this disease state.
The information provided on this page is for informational purposes only. The National Organization for Rare Disorders (NORD) does not endorse the information presented. The content has been gathered in partnership with the MONDO Disease Ontology. Please consult with a healthcare professional for medical advice and treatment.
The Genetic and Rare Diseases Information Center (GARD) has information and resources for patients, caregivers, and families that may be helpful before and after diagnosis of this condition. GARD is a program of the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).
View report
Your donation will help more than 30 million Americans with a rare disease navigate their diagnosis, receive financial assistance, and access the care and support they deserve. Make your tax-deductible gift today!